TrialInvestigational new drugs2015

Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors.

Andrea Cercek et al.PubMed ↗Publisher ↗

No numbers read from the abstract.